Ironwood Pharms Inc Drug Patent Portfolio

Ironwood Pharms Inc owns 2 orange book drugs protected by 9 US patents Given below is the list of Ironwood Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8546436 Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof 29 Feb, 2032
Active
US9956205 Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof 28 Dec, 2031
Active
US9216179 Treatment of gout and hyperuricemia 01 Aug, 2031
Active
US8357713 Compounds and compositions and methods of use 22 Dec, 2029
Active
US8084483 Compounds and compositions and methods of use 17 Aug, 2029
Active
US8546437 Compounds and compositions and methods of use 29 Apr, 2029
Active
US10183012 Compounds and compositions and methods of use 26 Nov, 2028
Active
US8283369 Compounds and compositions and methods of use 26 Nov, 2028
Active
US8003681 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester 25 Aug, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Ironwood Pharms Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 10 Jul, 2024 US8357713
Payment of Maintenance Fee, 12th Year, Large Entity 27 Mar, 2024 US8283369
Payment of Maintenance Fee, 12th Year, Large Entity 14 Jun, 2023 US8084483
Payment of Maintenance Fee, 8th Year, Large Entity 07 Jun, 2023 US9216179
Payment of Maintenance Fee, 12th Year, Large Entity 08 Feb, 2023 US8003681
Payment of Maintenance Fee, 4th Year, Large Entity 06 Jul, 2022 US10183012
Withdrawal of Application for PTE 21 Apr, 2022 US8084483
Withdrawal of Application for PTE 21 Apr, 2022 US8283369
Withdrawal of Application for PTE 21 Apr, 2022 US8003681
Withdrawal of Application for PTE 21 Apr, 2022 US8546437
Patent Term Extension Certificate 19 Apr, 2022 US8357713
Payment of Maintenance Fee, 4th Year, Large Entity 20 Oct, 2021 US9956205
Correspondence Address Change 01 Jun, 2021 US10183012
Correspondence Address Change 27 May, 2021 US8084483
Correspondence Address Change 27 May, 2021 US8283369


Ironwood Pharms Inc Drug Patents' Oppositions Filed in EPO

Ironwood Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 14, 2017, by Stada Arzneimittel Ag. This opposition was filed on patent number EP11853861A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11796324A Dec, 2018 Hexal AG Revoked
EP11796324A Dec, 2018 Bülle Dr., Jan Revoked
EP11796324A Dec, 2018 Alfred E. Tiefenbacher (GmbH & Co. KG) Revoked
EP11853861A Sep, 2017 Alfred E. Tiefenbacher (GmbH & Co. KG) Opposition rejected
EP11853861A Sep, 2017 STADA Arzneimittel AG Opposition rejected


Ironwood Pharms Inc's Family Patents

Ironwood Pharms Inc drugs have patent protection in a total of 41 countries. It's US patent count contributes only to 26.6% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Ironwood Pharms Inc Drug List

Given below is the complete list of Ironwood Pharms Inc's drugs and the patents protecting them.


1. Duzallo

Duzallo is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8546436 Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof 29 Feb, 2032
(7 years from now)
Active
US9956205 Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof 28 Dec, 2031
(7 years from now)
Active
US9216179 Treatment of gout and hyperuricemia 01 Aug, 2031
(6 years from now)
Active
US8357713 Compounds and compositions and methods of use 22 Dec, 2029
(5 years from now)
Active
US8084483 Compounds and compositions and methods of use 17 Aug, 2029
(4 years from now)
Active
US8546437 Compounds and compositions and methods of use 29 Apr, 2029
(4 years from now)
Active
US10183012 Compounds and compositions and methods of use 26 Nov, 2028
(4 years from now)
Active
US8283369 Compounds and compositions and methods of use 26 Nov, 2028
(4 years from now)
Active
US8003681 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester 25 Aug, 2025
(9 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Duzallo's drug page


2. Zurampic

Zurampic is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8546436 Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof 29 Feb, 2032
(7 years from now)
Active
US9956205 Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof 28 Dec, 2031
(7 years from now)
Active
US9216179 Treatment of gout and hyperuricemia 01 Aug, 2031
(6 years from now)
Active
US8357713 Compounds and compositions and methods of use 22 Dec, 2029
(5 years from now)
Active
US8084483 Compounds and compositions and methods of use 17 Aug, 2029
(4 years from now)
Active
US8546437 Compounds and compositions and methods of use 29 Apr, 2029
(4 years from now)
Active
US10183012 Compounds and compositions and methods of use 26 Nov, 2028
(4 years from now)
Active
US8283369 Compounds and compositions and methods of use 26 Nov, 2028
(4 years from now)
Active
US8003681 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester 25 Aug, 2025
(9 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurampic's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List